

Children's Mercy Kansas City

## SHARE @ Children's Mercy

---

Manuscripts, Articles, Book Chapters and Other Papers

---

3-2020

### Energy and protein requirements for children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce.

Vanessa Shaw

Nonnie Polderman

José Renken-Terhaerd

Fabio Paglialonga

Michiel Oosterveld

*See next page for additional authors*

Let us know how access to this publication benefits you

Follow this and additional works at: <https://scholarlyexchange.childrensmercy.org/papers>



Part of the [Dietetics and Clinical Nutrition Commons](#), [Nephrology Commons](#), and the [Pediatrics Commons](#)

---

#### Recommended Citation

Shaw V, Polderman N, Renken-Terhaerd J, et al. Energy and protein requirements for children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. *Pediatr Nephrol.* 2020;35(3):519-531. doi:10.1007/s00467-019-04426-0

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact [hlsteel@cmh.edu](mailto:hlsteel@cmh.edu).

---

**Creator(s)**

Vanessa Shaw, Nonnie Polderman, José Renken-Terhaerd, Fabio Paglialonga, Michiel Oosterveld, Jetta Tuokkola, Caroline Anderson, An Desloovere, Laurence Greenbaum, Dieter Haffner, Christina Nelms, Leila Qizalbash, Johan Vande Walle, Bradley A. Warady, Rukshana Shroff, and Lesley Rees



# Energy and protein requirements for children with CKD stages 2-5 and on dialysis—clinical practice recommendations from the Pediatric Renal Nutrition Taskforce

Vanessa Shaw<sup>1,2</sup> · Nonnie Polderman<sup>3</sup> · José Renken-Terhaerd<sup>4</sup> · Fabio Paglialonga<sup>5</sup> · Michiel Oosterveld<sup>6</sup> · Jetta Tuokkola<sup>7</sup> · Caroline Anderson<sup>8</sup> · An Desloovere<sup>9</sup> · Laurence Greenbaum<sup>10</sup> · Dieter Haffner<sup>11</sup> · Christina Nelms<sup>12</sup> · Leila Qizalbash<sup>13</sup> · Johan Vande Walle<sup>9</sup> · Bradley Warady<sup>14</sup> · Rukshana Shroff<sup>15,16</sup> · Lesley Rees<sup>15,16</sup>

Received: 30 September 2019 / Revised: 8 November 2019 / Accepted: 19 November 2019 / Published online: 16 December 2019  
© The Author(s) 2019

## Abstract

Dietary management in pediatric chronic kidney disease (CKD) is an area fraught with uncertainties and wide variations in practice. Even in tertiary pediatric nephrology centers, expert dietetic input is often lacking. The Pediatric Renal Nutrition Taskforce (PRNT), an international team of pediatric renal dietitians and pediatric nephrologists, was established to develop clinical practice recommendations (CPRs) to address these challenges and to serve as a resource for nutritional care. We present CPRs for energy and protein requirements for children with CKD stages 2–5 and those on dialysis (CKD2–5D). We address energy requirements in the context of poor growth, obesity, and different levels of physical activity, together with the additional protein needs to compensate for dialysate losses. We describe how to achieve the dietary prescription for energy and protein using breastmilk, formulas, food, and dietary supplements, which can be incorporated into everyday practice. Statements with a low grade of evidence, or based on opinion, must be considered and adapted for the individual patient by the treating physician and dietitian according to their clinical judgment. Research recommendations have been suggested. The CPRs will be regularly audited and updated by the PRNT.

**Keywords** Energy · Protein · Chronic kidney disease · Pediatric Renal Nutrition Taskforce · Clinical practice recommendations

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s00467-019-04426-0>) contains supplementary material, which is available to authorized users.

✉ Vanessa Shaw  
vanessa.shaw@plymouth.ac.uk

<sup>1</sup> University of Plymouth, Plymouth PL6 8BH, UK

<sup>2</sup> University College London Institute of Child Health, London, UK

<sup>3</sup> British Columbia Children's Hospital, Vancouver, Canada

<sup>4</sup> Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands

<sup>5</sup> Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy

<sup>6</sup> Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, The Netherlands

<sup>7</sup> Children's Hospital and Clinical Nutrition Unit, Internal Medicine and Rehabilitation, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

<sup>8</sup> Southampton Children's Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, UK

<sup>9</sup> University Hospital Ghent, Ghent, Belgium

<sup>10</sup> Emory University and Children's Healthcare of Atlanta, Atlanta, USA

<sup>11</sup> Children's Hospital, Hannover Medical School, Hannover, Germany

<sup>12</sup> PedsFeeds LLC, University of Nebraska, Lincoln, USA

<sup>13</sup> Great Northern Children's Hospital, Newcastle Upon Tyne, UK

<sup>14</sup> Children's Mercy, Kansas City, USA

<sup>15</sup> Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

<sup>16</sup> The Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and Institute of Child Health, University College London, London, UK

## Introduction

Poor nutrition is one of the best described causes of poor growth in children with chronic kidney disease (CKD) (1). Malnutrition is also associated with worsening uremic symptoms and can lead to protein-energy wasting and increased mortality. Conversely, obesity is a worldwide problem that is also increasingly affecting the CKD population (2).

In 2009, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) published comprehensive nutritional guidelines (3). The Pediatric Renal Nutrition Taskforce (PRNT) provides clinical practice recommendations (CPRs), updated wherever there is new evidence subsequent to the publication by KDOQI, on various aspects of the dietary management of children with kidney diseases; this document focuses on energy and protein requirements. The composition of the PRNT, limitations, and grading of evidence, and plans for audit and revision of the CPRs have been previously described (4).

Nutritional assessment is necessary to determine an individual's dietary prescription; the methods and tools for this assessment are described in the KDOQI guidelines (3). Additional information about nutritional management in CKD not covered here, including potassium, sodium, and micronutrients, is discussed by KDOQI (3) and will be addressed by the PRNT in future CPRs. As with all documents produced by the PRNT, the practical day-to-day management of the nutritional prescription will be developed by the Taskforce during the dissemination phase of the guideline (4).

## Methods

Existing guidelines on energy and protein requirements for age and gender in healthy children were reviewed and used to help determine recommendations for children with CKD stages 2–5 and when on dialysis (CKD2–5D).

## Terminology

The recommendations for dietary requirements for energy and nutrients, published by national and international health bodies, are expressed in various terms and represent different measures. These are detailed in the Supplementary Tables 1a and 1b.

We have not endorsed any one set of published values for energy and protein requirements but have taken a pragmatic approach and taken the range of requirements from the national health bodies for our recommendations. Since the national and international terms for energy and protein requirements have different definitions (and are therefore not directly comparable), and as we show a range of the published values, we will use a novel term: Suggested Dietary Intake (SDI) for our

recommendations. The SDI comprises a range of values. The lower and upper limits of the SDI for energy fall within the average amount given in the published values (i.e., the daily amount of energy considered sufficient to meet the needs of half the population). The lower and upper limits of the SDI for protein fall within the average amount + 2 SD given in the published values (i.e., the daily amount of protein considered sufficient to meet the needs for nearly all (97.5%) of the population) (Supplementary Fig. 1). The SDI may be used for formulating dietary prescriptions and assessing the adequacy of dietary intake in individuals.

## Development process

The full development process for the CPRs and their purpose has been published (4). PICO (Patient, Intervention, Comparator, and Outcome) questions have been developed in order to develop recommendations that provide specific actionable advice, including choosing between alternative approaches in particular clinical situations.

*PICO questions*

*Population:* Children from birth to 18 years of age with CKD2–5D.

*Intervention:* Nutritional requirements for energy and protein in children at different stages of CKD.

*Comparator:* Nutritional requirements for energy and protein in age-matched healthy children.

*Outcomes:* Energy and protein requirements to support normal growth and development in children with CKD2–5D.

## Literature search

Details of the literature search are described in Supplementary Table 2. After a critical review of the literature for each PICO question, CPRs were derived and graded using the American Academy of Pediatrics grading matrix (5) (Supplementary Table 3). The Delphi method was used as previously described (4) to seek consensus from experts in the field.

## Clinical practice recommendations

### 1. What are the energy requirements for children with CKD stages 2–5D?

1.1 We suggest that the initial prescription for energy intake in children with CKD2–5D should approximate that of healthy children of the same chronological age. (Level B; moderate recommendation).

1.2 To promote optimal growth in those with suboptimal weight gain and linear growth, we suggest that energy intake should be adjusted towards the higher end of the suggested dietary intake (SDI). (Level D; weak recommendation).

1.3 In overweight or obese children, adjust energy intake to achieve appropriate weight gain, without compromising nutrition. (Level X; strong recommendation).

## Evidence and rationale

**Healthy children** The optimal energy requirement is the energy from food needed to maintain normal body mass, growth, and development, and to support a level of physical activity consistent with long-term good health. Energy requirements are affected by physical activity, growth, lean body mass, genetics, ethnicity, the environment, and current nutritional status.

Recommendations for energy intake come from observational and experimental studies and, more recently, studies using doubly labeled water (DLW) along with a factorial method to address physical activity (6–13). The DLW technique is considered the “gold standard” for assessing total energy expenditure (TEE) in free-living individuals. TEE includes physical activity energy expenditure (the most variable component of TEE), resting energy expenditure (REE), and the thermic effect of food.

There are many guidelines for energy requirements (Supplementary Table 4a) for the healthy population (6–13). The definitions for the terms used are in Supplementary Table 1a.

**Children with CKD2–5D** The 2009 KDOQI guidelines recommend an energy intake for children with CKD stages 2–5D of 100% of the estimated energy requirement (EER) for chronological age and that further adjustment to energy intake should be based upon the response in terms of the rate of weight gain or loss (3). These statements were level B recommendations. Subsequent studies provide no reason to change these guidelines, but we suggest using the SDI to serve as the standard for energy requirements (Table 1).

There have been two strategies to investigate the optimal requirements for energy for children with CKD since publication of the KDOQI guidelines. First, four trials studied REE/basal metabolic rate (BMR) by indirect calorimetry and showed no difference from healthy children after adjustment for lean body mass (14–17). One trial measured BMR by indirect open circuit calorimetry in 20 children with CKD and 20 healthy age- and gender-matched controls (17). The adjusted BMR of children with CKD did not differ significantly from healthy subjects. Second, observational and retrospective studies have reported the effects of specified energy intake measurements in children with CKD (18–40). Most reported that dietary energy intakes of around 100% of EER in children with CKD, managed conservatively or on peritoneal dialysis, resulted in acceptable growth (19–25, 30, 32, 33). The largest prospective trial enrolled 65 children aged 2 to 16 years with an estimated glomerular filtration rate (eGFR) < 75 ml/min/

1.73 m<sup>2</sup> body surface area (BSA) (40). In the 51 completing the study, growth was normal with median energy intakes of 94–98% of estimated average requirement (EAR) at baseline and 85–94% of EAR at 2 years of follow-up.

In children on peritoneal dialysis (PD), energy intake from dialysate must be considered, with reports of  $7.5 \pm 7$  to  $9.08 \pm 4.13$  kcal/kg/day (41, 42), depending on peritoneal glucose exposure (glucose concentration of the dialysate, time on dialysis, cycles, and dwell times) and peritoneal membrane transporter status. While some children may benefit from this additional energy, if there is excessive weight gain, this energy source needs to be taken into account when considering the balance of macronutrients (protein, carbohydrate and fat) provided by the diet.

Indeed, obesity is increasing worldwide, even in children with CKD: the International Pediatric PD Network (IPPN) registry found a 19.7% prevalence of overweight/obesity in children at the start of chronic PD (compared with 8.9% underweight) (2). The Chronic Kidney Disease in Children (CKiD) study has shown the median energy and protein consumption to be higher than recommended in all age groups, implying that at least half the children consumed more energy and protein than recommended (43, 44). Modification of energy intake and lifestyle changes, including physical activity, may be needed (3).

## 2. What are the protein requirements for children with CKD stages 2–5D?

2.1 We suggest that the target protein intake in children with CKD2–5D is at the upper end of the SDI to promote optimal growth. (Level C; moderate recommendation). The protein intake at the lowest end of the range is considered the minimum safe amount and protein intake should not be reduced below this level. (Level X; strong recommendation).

2.2 We suggest that the protein intake in children on dialysis may need to be higher than the SDI for non-dialysis patients to account for dialysate protein losses. (Level C; weak recommendation).

2.3 In children with persistently high blood urea levels, we suggest that protein intake may be adjusted towards the lower end of the SDI, after excluding other causes of high blood urea levels. (Level C; moderate recommendation).

## Evidence and rationale

**Healthy children** The protein requirement is the amount of protein needed for growth and to balance the losses of nitrogen from the body in individuals maintaining energy balance. We have considered all recent reports citing daily protein needs and we have focused on those using the linear regression approach and the factorial method to inform their

**Table 1** Energy and protein requirements for infants, children and adolescents with CKD2–5D aged 0–18 years

SDI for energy and protein: birth <sup>a</sup> to 18 years				
Month	SDI <sup>b</sup> energy (kcal/kg/day)	SDI protein (g/kg/day)	SDI protein (g/day)	
0	93–107	1.52–2.5	8–12	
1	93–120	1.52–1.8	8–12	
2	93–120	1.4–1.52	8–12	
3	82–98	1.4–1.52	8–12	
4	82–98	1.3–1.52	9–13	
5	72–82	1.3–1.52	9–13	
6–9	72–82	1.1–1.3	9–14	
10–11	72–82	1.1–1.3	9–15	
12	72–120	0.9–1.14	11–14	
Year	SDI energy (kcal/kg/day)		SDI protein (g/kg/day)	SDI protein (g/day)
–	Male	Female		
2	81–95 <sup>c</sup>	79–92 <sup>c</sup>	0.9–1.05	11–15
3	80–82	76–77	0.9–1.05	13–15
4–6	67–93	64–90	0.85–0.95	16–22
7–8	60–77	56–75	0.9–0.95	19–28
9–10	55–69	49–63	0.9–0.95	26–40
11–12	48–63	43–57	0.9–0.95	34–42
13–14	44–63	39–50	0.8–0.9	34–50
15–17	40–55	36–46	0.8–0.9	Male: 52–65 Female: 45–49

For children with poor growth, reference to the SDI for height age may be appropriate. Height age is the age that corresponds to an individual's height when plotted on the 50th centile on a growth chart

<sup>a</sup> Thirty-seven/40 weeks gestation. Premature infants have higher energy and protein requirements. The increased need for these and other particular nutrients (sodium, potassium, calcium, and phosphorus) must be balanced against the nutritional interventions to control the effects of CKD. This is outside the scope of this CPR

<sup>b</sup> Suggested Dietary Intake (SDI) is based on the Physical Activity Level (PAL) used by the international bodies: 1–3 year PAL 1.4; 4–9 year PAL 1.6; and 10–17 year PAL 1.8. Where guidelines have given a range of energy requirements for different levels of PAL, the lowest PAL has been taken for SDI energy in consideration that children with CKD are likely to have low activity levels

<sup>c</sup> Scientific Advisory Committee on Nutrition (9) reports energy requirements as kcal/day: male 1040 kcal/day; female 932 kcal/day

guidelines (7, 8, 10, 13, 45–48) (Supplementary Table 4b). Age-appropriate ranges from these guidelines have been adopted to create the SDI for protein. The data from Agence Française de Sécurité Sanitaire des Aliments (AFSSA) (48) have been excluded due to the wide range of values given which lie outside of the ranges of the other guidelines considered.

Protein is a fundamental component of cellular and organ function. Together with sufficient protein provision, there must also be adequate non-protein energy (i.e., carbohydrates, fats) available in order that the carbon skeletons of amino acids are not utilized to meet energy needs (49). Furthermore, unless amino acids are present in the correct balance in an individual's diet, protein utilization will be negatively affected (49). Dietary protein is needed to maintain protein turnover and to synthesize physiologically important products of amino acid metabolism to lay down as new tissue.

Nitrogen balance can be used to derive estimates of nitrogen protein requirements. The usual approach is based on the regression of nitrogen balance (the equilibrium between intake and loss) on intake. The average protein requirement is based on nitrogen loss by urine, stool, hair, nails, and transpiration (50) plus the extra protein needed for growth (51). The nitrogen amount is calculated and converted to protein with the factor 6.25. The protein requirements for individuals following lacto-ovo vegetarian and vegan diets, in order to achieve the right amount and balance of high quality protein, are 1.2 and 1.3 times higher, respectively, than for people consuming a mixed animal- and plant-based diet (8) due to the lower bioavailability of non-animal protein.

**Children with CKD2–5D** The 2009 KDOQI guidelines (3) suggested maintaining an intake of dietary protein at 100 to 140% of the dietary reference intake (DRI) for ideal body weight in children with CKD stage 3 and at 100 to 120% of the DRI in children

with CKD stages 4 to 5 (level C). In children with CKD stage 5D, it was suggested that dietary protein intake be maintained at 100% of the DRI for ideal body weight plus an allowance for dialytic protein and amino acid losses: for patients on PD 0.15–0.3 g/kg/day and for patients on hemodialysis (HD) 0.1 g/kg/day (level C) (3). Since the publication of the KDOQI guidelines, there have been no studies that support adjustment of the above statements, but we suggest using the SDI to serve as the standard for protein requirements (Table 1).

Two randomized controlled trials (RCTs) have compared low protein versus normal protein diets in children with CKD (52, 53). At 8 months of age, 24 infants with an eGFR < 55 ml/min/1.73 m<sup>2</sup> were randomized to receive for 10 months either a low protein formula of 1.4 ± 0.3 g/kg/day, with a protein-energy (PE) ratio (the percentage of total dietary energy derived from protein) of 5.6%; or control protein (2.4 ± 0.4 g/kg/day; PE ratio of 10.4%). Significantly lower standard deviation scores (SDS) for length and growth velocity were found in the low protein diet group compared with controls (52). In the second trial, 226 CKD patients aged between 2 and 18 years were randomized to the lowest safe protein intake (0.8 to 1.1 g/kg/day), as recommended by the World Health Organization (WHO) (46), versus an unrestricted protein intake; all patients were advised to have a calorie intake of at least 70% of the WHO recommendations. After 2 years of follow-up, neither the primary endpoint (change in creatinine clearance) nor growth was different between the two groups (53). A Cochrane meta-analysis in 2007 concluded that there was uncertainty over the possibility of harm associated with the provision of strict low protein diets on growth in young infants (54).

Nitrogen balance studies are another option to estimate the protein requirements of a specific population. In a study of 31 children on PD, a dietary protein intake of at least 1.45 g/kg/day (= 144% of recommended daily allowance (RDA)) was required to obtain an estimated nitrogen balance of + 50 mg/kg/day (55).

Based on the available evidence, restriction of dietary protein in the early stages of CKD in children should be avoided. Most importantly, a low protein intake may increase the risk of malnutrition, poor growth, and protein-energy wasting, which are common problems in this population. The ranges for protein SDI given here are a starting point for the initial prescription of dietary protein for feeding a child with CKD. Some children will be consuming a higher protein intake, which can negatively affect acid-base balance and urea levels; phosphate intake is also higher in patients with a high protein intake (56–59). In 20 children on PD, dietary protein intake was negatively correlated with plasma bicarbonate, total body bone mineral density, bone mineral content, and fat-free mass (56). The impact of high phosphate intake is discussed elsewhere (4).

PD is associated with significant protein losses in the dialysate, and losses are higher in small children on chronic PD compared to older children, ranging from 0.28 g/kg/day in

infants to 0.1 g/kg/day in adolescents (60); in turn, it is reasonable to suggest that protein intake should be increased accordingly. Peritoneal transport status characteristics and the increase of peritoneal protein losses during peritonitis should also be taken into account. There are no pediatric studies of amino acid and protein losses in extracorporeal dialysis, while amino acid losses as high as 6–10 g/session have been reported in adults treated with HD (61–63).

Children on intensified HD or hemodiafiltration often have an unrestricted diet, as these dialysis modalities allow for better volume and metabolic control (64).

Given the deleterious effects of acidosis and phosphate load in children with CKD, a reduction of protein intake could, in some cases, help improve metabolic control provided that nutritional status is preserved. Urea levels may be used as an indicator of protein intake and may help determine when a reduction in dietary protein intake might be considered. It is not expected that children with CKD2–5D have urea levels in the normal range. Indeed, low levels may indicate insufficient dietary protein. In contrast, urea levels chronically higher than expected for the degree of CKD are most commonly due to excessive dietary protein relative to energy intake but may also be secondary to a catabolic state, acute or chronic dehydration, or steroid therapy. The urea level associated with uremic symptoms is variable with age and between individuals. Chronically high urea levels may be tolerated.

### 3. How is the nutritional prescription for energy and protein provided for children with CKD stages 2–5D?

3.1 Breastfeeding is the preferred method for feeding an infant with CKD. (Level X; strong recommendation).

3.2 When breastfeeding is not possible or expressed breastmilk is not available in adequate amounts for the infant with CKD, we suggest that whey-dominant infant formulas be used. (Level A; strong recommendation).

3.3 We suggest that breastmilk and infant formulas should be fortified when there is a prescribed fluid restriction or when a more energy or nutrient dense feed is required to meet nutritional requirements. (Level A ; strong recommendation).

3.4 We suggest that the concentration of feeds and addition of dietary supplements are prescribed in a gradual manner in order to maximize acceptance and tolerance. (Level D; weak recommendation).

### Evidence and rationale

Breastmilk is the best source of nutrition for infants (65), including those with CKD2–5D who may benefit from its low renal solute load. Standard whey-dominant infant formulas have a protein and electrolyte content closer to that of

breastmilk than casein-dominant formulas, so are the preferred alternative and may be beneficial beyond the first year of life. Do not use soya infant formulas under 12 months of age due to their high phytoestrogen content, unless there is a specific medical indication.

The nutritional content of infant formulas may be concentrated in a smaller volume when there is a need for fluid restriction, or when normal feed volumes exacerbate vomiting and gastro-esophageal reflux. Most standard infant formulas are reconstituted to an approximate 13% concentration (i.e., 13 g powder to 100 ml water, providing 67 kcal and 1.3 g protein per 100 ml). It is suggested that this concentration may be increased daily by 1–3%, up to 20% (i.e., 20 g powder to 100 ml water), depending on local practices and the infant's tolerance of feed changes. Infant formula powder may also be added to expressed breastmilk (EBM) at a concentration of 3–6% (i.e., 3–6 g infant formula powder to 100 ml EBM), increasing the total energy density up to 1 kcal/ml. Breastmilk fortifier may also be used for preterm infants.

Concentrating the formula should be done gradually to ensure tolerance since the increase in osmolality (66) may cause diarrhea, vomiting, and gastro-esophageal reflux. It also increases the renal solute load and may lead to excessive intakes of phosphate, potassium, and other minerals and vitamins. Toxic levels of vitamin A are of particular concern (67). In contrast, the majority of water-soluble vitamins are below the dietary reference intake (DRI) (68, 69). In patients on dialysis, certain vitamins (water-soluble vitamins B1, B5, B6, folic acid, vitamin C) and zinc are lost excessively in the dialysate; these may need to be supplemented over and above the levels provided by the formula to meet recommended intakes. Recommendations regarding the vitamin intake for children with CKD are included in the KDOQI guidelines (3).

An alternative is to use an infant formula at a normal concentration (or EBM if available) and to add protein powder and/or energy modules (glucose polymers, fat emulsions, or combined carbohydrate and fat preparations) to design a patient-specific profile for energy and protein, with attention to vitamin and mineral supplementation as necessary (24, 70, 71). This method of fortification is particularly used if concentrating the infant formula provides an intake of vitamin A, potassium, or phosphate beyond desirable levels. A simple recipe and caregiver education are required to reduce errors in formula preparation (72). Energy and nutrient dense liquid infant formulas are available commercially and may be useful. The addition of glucose polymers, fat emulsions, and protein powders to standard infant formula and EBM can be used for oral feeding or tube feeding. If a mother wishes to continue breastfeeding, this should be prioritized and incorporated into the feeding plan as long as the infant's overall nutritional intake is not compromised.

To achieve optimal growth in the healthy infant with appropriate deposition of lean and fat tissue, the PE ratio of the

infant formula should ideally be within the range 7–12%; a high PE ratio is required for accelerated weight gain or catch-up growth (Supplementary Table 5) (46). In CKD, the challenge is to preserve the PE ratio while adding non-protein energy sources (carbohydrate and fat) to formula in order to control abnormal blood biochemistry, such as elevated urea, phosphate, or potassium levels. In these situations, it is important to ensure that at least the SDI for protein is provided. A PE ratio of 5.3–6.4% supported weight gain and linear growth in children aged 0–2 years, provided at least 100% of protein requirements were given (21), the lower PE ratio reflecting an increase in energy provision rather than a low protein intake.

Glucose polymers may be added in increments, e.g., 1% daily (1 g extra added to 100 ml formula or EBM per day, yielding an additional 4 kcal/100 ml). Gradual increases will allow for identification of the concentration at which the infant becomes intolerant (developing loose stools, increased vomiting). Tolerance to increased carbohydrate concentration depends on the age of the infant, and the maturity and absorptive capacity of the gut, with some infants more tolerant to a more rapid addition of a glucose polymer.

Fat emulsions may be used and should also be added incrementally, e.g., 1% daily (1 ml added to 100 ml formula or EBM per day) to provide an increase of 0.5 g fat per 100 ml (an additional 5 kcal/100 ml). The increased fat content may delay gastric emptying and cause nausea and vomiting. See Table 2 for suggested percentage concentrations of carbohydrate and fat that may be tolerated.

Hyperkalemia occurs as CKD progresses and is more pronounced in patients with metabolic acidosis. Usually reduced potassium intake is indicated (3), but hyperkalemia can result from cell catabolism when there is deficient energy intake. This can be resolved by the addition of energy modules to the infant's usual formula or EBM.

Protein powders are added to formulas or EBM to provide a specific amount of protein per kilogram of body weight. Additional protein is particularly important for the child on PD to compensate for protein losses in dialysate (60). Protein intake should be increased by at least 0.15–0.3 g/kg/day for children on PD, 0.1 g/kg/day for HD (3). Supplements should be added in small increments, 0.1 g protein/kg/day, and urea levels measured to detect excessive intake (i.e., urea levels above expected for degree of CKD). On occasion, measurement of dialysis protein losses may help guide a plan for protein supplementation.

3.5 Solid foods should be introduced as recommended for healthy infants, with progression to varied textures and content according to the infant's cues and oral motor skills. We suggest that all children eat a healthy, balanced diet with a wide variety of food choices, as for the general population,



**Table 2** Suggested addition of energy modules to formulas

Energy module	Age	Amount of CHO/fat module added to formula	Final concentration of CHO/fat in formula (% or g/100 mL)
Glucose polymer	< 6 months	3–5 g (+ 7 g CHO from infant formula <sup>a</sup> )	10–12
	6 months–1 year	5–8 g (+ 7 g CHO from infant formula <sup>a</sup> )	12–15
	> 1 year	8–18 g (+ 12 g CHO from pediatric formula <sup>a</sup> )	20–30
Fat emulsion (50% fat content)	< 1 year	3–5 ml (+ 3.5 g fat from infant formula <sup>a</sup> )	5–6
	> 1 year	9 ml (+ 4.5 g fat from pediatric formula <sup>a</sup> )	9

Adapted from Shaw V (ed) *Clinical Paediatric Dietetics*, 4th edition (2015). Chichester: Wiley Blackwell, page 18

CHO carbohydrate

<sup>a</sup> CHO and fat contents of formulas vary

taking into account possible dietary limitations. (Level D; weak recommendation).

3.6 Oral feeding is the preferred route whenever possible. Oral stimulation is desirable, even if oral intake is limited, to prevent the development of food aversion. (Level C; weak recommendation).

## Evidence and rationale

Whilst exclusive breastfeeding for the first 6 months of life is recommended by the WHO and supported by a systematic review (65), the age when solid foods are introduced for infants with CKD should be managed individually. Delayed exposure to pureed and more textured foods may cause feeding problems (73). The nutritional content of solid food must be balanced against that provided by the formula in order to achieve optimum intake of energy, protein, and other nutrients. Dietary limitations in potassium and phosphate may be necessary according to the stage of CKD and abnormal blood biochemistry. A low potassium or phosphate formula may be given so that dietary restrictions can be liberalized to allow a greater variety of foods to be offered. A more liberal oral intake may encourage more normal development and behaviors around food.

From 1 year of age, commercially available fortified milk drinks (with a suitably low phosphate and potassium content) may be useful as they contain iron, vitamin D, and n-3 polyunsaturated fatty acids, which may enhance the diet of the toddler with CKD. Also known as “Young Child Formulas,” they are not routinely recommended for healthy children (74).

Infants and young children with CKD2–5D may be reluctant to take an oral diet. At the same time, tube feeding is associated with long-lasting feeding difficulties, such as chewing and swallowing problems, food refusal, panic attacks (75), and poor development of oral motor skills (73). An important aspect of nutritional treatment is therefore to enable as normal development of feeding and eating as possible. When

there are significant feeding difficulties, speech and language therapy may help caregivers with the provision of oral feeding and with non-nutritive oral stimulation; input from a psychologist, including family therapy, may be considered (73).

Whilst encouraging an oral diet, there is a need to educate families about healthier food choices at the time of introduction of solids in order to influence later dietary habits. Besides undernutrition, obesity is common in the CKD population and the frequency is similar to that of the normal population. A food frequency questionnaire (FFQ) in 658 children aged 2–18 years with mild to moderate CKD in North America has highlighted some undesirable eating habits (44). Fast foods were a major contributor of sodium, phosphorus, energy, and fat intake, with cow’s milk and milk products contributing 7.7% of energy, 13.8% of protein, 4.6% of sodium, 20.3% of phosphate, and 15.9% of potassium intakes. Dietary and lifestyle changes to achieve weight control are discussed by KDOQI (3).

3.7 We suggest prompt intervention once deterioration in weight centile is noted. Oral nutritional supplementation should be started in children with inadequate dietary intake, after consideration of medical management of correctable causes of reduced intake. (Level B, moderate recommendation).

## Evidence and rationale

Growth is most rapid in the first year of life, and failure to gain weight is the signal for intervention. If weight is static for just 2 weeks in the first 3 months of life, there is a loss of 1 centile; if static for 4 weeks, 2 centiles are lost; at 6 months of age, there is a loss of 1 centile after a 3 week period of no weight gain; and at 9 months, 1 centile is lost after 4 weeks of static weight. Weight and/or head circumference measurements are more sensitive markers of poor growth in infants with CKD when length/height measurements are often inaccurate.

**Table 3** Summary of recommendations

Category	Recommendation	Grade
1 Energy requirements	1.1 We suggest that the initial prescription for energy intake in children with CKD2–5D should approximate that of healthy children of the same chronological age.	Level B; moderate recommendation
	1.2 To promote optimal growth in those with suboptimal weight gain and linear growth, we suggest that energy intake should be adjusted towards the higher end of the suggested dietary intake (SDI).	Level D; weak recommendation
	1.3 In overweight or obese children, adjust energy intake to achieve appropriate weight gain, without compromising nutrition.	Level X; strong recommendation
2 Protein requirements	2.1 We suggest that the target protein intake in children with CKD2–5D is at the upper end of the SDI to promote optimal growth. The protein intake at the lowest end of the range is considered the minimum safe amount and protein intake should not be reduced below this level.	Level C; moderate recommendation Level X; strong recommendation
	2.2 We suggest that the protein intake in children on dialysis may need to be higher than the SDI for non-dialysis patients to account for dialysate protein losses.	Level C; weak recommendation
	2.3 In children with persistently high blood urea levels, we suggest that protein intake may be adjusted towards the lower end of the SDI, after excluding other causes of high blood urea levels.	Level C; moderate recommendation
3 Nutritional prescription	3.1 Breastfeeding is the preferred method for feeding an infant with CKD.	Level X; strong recommendation
	3.2 When breastfeeding is not possible or expressed breastmilk is not available in adequate amounts for the infant with CKD, we suggest that whey-dominant infant formulas be used.	Level A; strong recommendation
	3.3 We suggest that breastmilk and infant formulas should be fortified when there is a prescribed fluid restriction or when a more energy or nutrient dense feed is required to meet nutritional requirements	Level A; strong recommendation
	3.4 We suggest that the concentration of feeds and addition of dietary supplements are prescribed in a gradual manner in order to maximize acceptance and tolerance.	Level D; weak recommendation
	3.5 Solid foods should be introduced as recommended for healthy infants, with progression to varied textures and content according to the infant's cues and oral motor skills. We suggest that all children eat a healthy, balanced diet with a wide variety of food choices, as for the general population, taking into account possible dietary limitations.	Level D; weak recommendation
	3.6 Oral feeding is the preferred route whenever possible. Oral stimulation is desirable, even if oral intake is limited, to prevent the development of food aversion.	Level C, weak recommendation
	3.7 We suggest prompt intervention once deterioration in weight centile is noted. Oral nutritional supplementation should be started in children with inadequate dietary intake, after consideration of medical management of correctable causes of reduced intake.	Level B, moderate recommendation
	3.8 We suggest that supplemental or exclusive enteral tube feeding should be commenced in children who are unable to meet their nutritional requirements orally, in order to improve nutritional status.	Level B, moderate recommendation

The first step in response to poor weight gain is to address any correctable causes of reduced dietary intake, such as gastro-esophageal reflux/vomiting (by means of feed thickeners, alginates, antacids, histamine H2 receptor antagonists, proton pump inhibitors, sucralfate, prokinetics), acidosis, volume overload, or inadequate dialysis. Children with CKD may also not achieve adequate oral intake due to reduced appetite, altered smell and taste, and abnormal hormone regulation (76–88) (Supplementary Table 6). When inadequate energy and protein intake persists, nutritional supplementation should be instituted. Many studies in children with CKD suggest that growth deteriorates without supplemental feeding and that with dietary intervention by the oral route or with enteral tube feeding, this deterioration can be diminished (18, 21, 22, 29, 36, 38, 40, 43, 89–95). In children with salt-wasting forms of CKD, salt supplementation is also necessary for optimal growth (3).

Energy and protein modules can be added to EBM, standard infant formulas, and infant renal specific formulas. Alternatively, standard pediatric enteral formulas can be

fortified if the child will drink them. Standard adult enteral and renal specific formulas can be modified, if necessary, to meet the nutritional requirements of infants and children, but with particular attention to their vitamin and mineral content, which may be excessive.

For those children who are eating, these modules can also be added to normal foods and beverages to meet energy and protein requirements. Where vitamin and mineral intake is also lacking, the first line of treatment is to give nutritionally complete oral liquids (also known as oral nutritional supplements or sip feeds) suitable for toddlers, older children, and adolescents. If there are concerns with elevated electrolyte levels, a palatable high energy pediatric renal specific oral nutritional supplement can be used, when available.

Glucose polymers can be added to beverages, starting with 5% (5 g added to 100 ml) and increasing to 20–30% as needed, and also to “liquid” foods such as porridge/hot breakfast cereals and custards/soft desserts. Sugar and glucose may also be used, but the quantity may be limited due to their sweet taste and osmotic effect on the gut. Extra fat in the form of

vegetable margarines or oils (preferably those with a high content of omega-3 fats, such as olive, walnut, or rapeseed oil), and jams, honey, or syrups can be added to foods. Other options include alternative “milks” derived from plants, such as soy, oat, almond, or coconut, without calcium phosphate fortification. It is not advisable to give rice milk to infants and young children due to its high arsenic content. Fruit juices, or alternatively concentrated fruit flavorings (cordials) if there is hyperkalemia, can be provided; protein-free milk replacement drinks, which have low phosphate contents, can serve as a supplement. Glucose absorbed from PD fluid (41, 42) contributes to total energy intake.

It is rarely necessary to add protein modules to foods for children with CKD2–5, but they may be useful for those on dialysis, choosing low phosphate preparations. Most liquid oral renal specific supplements designed for adults are low volume and can be provided between meals in small portions without compromising appetite.

No recommendation can be made for using dietary supplements of essential amino acids and ketoacids in children with CKD. In a trial with 20 children and adolescents, a low protein diet (0.6 g/kg/day) with ketoacid supplements led to a statistically significant ( $p < 0.001$ ) increase in height SD (from  $-1.93 \pm 1.76$  to  $-1.37 \pm 1.58$ ) when compared to a diet providing the RDA for protein (96). A study of 20 infants with an eGFR  $< 30$ – $75$  ml/min/1.73 m<sup>2</sup> (not tube fed), and a diet containing 1.8–2.2 g protein/kg/day with supplemental essential amino acids accounting for 20% of the protein intake showed a decrease in weight and height SD from birth to 12 months:  $-0.26$  to  $-1.53$  and  $-0.56$  to  $-1.63$ , respectively (97).

3.8 We suggest that supplemental or exclusive enteral tube feeding should be commenced in children who are unable to meet their nutritional requirements orally, in order to improve nutritional status. (Level B, moderate recommendation).

## Evidence and rationale

Several retrospective studies in children with CKD have shown improvement in weight/BMI SD with tube feeding (18, 21, 22, 91–95). All but two of these studies (91, 95) also showed an improvement in height SD. Although most of the available evidence is for children under the age of 2 years, one study reported an increase in weight and height SD specifically for children aged 2–5 years with tube feeding (21). In these studies, tube feeds provided as much as 100% of requirements, while others were supplemental to oral intake.

Three studies have not shown an association between tube feeding and growth. In a questionnaire-based nested case-control study on 137 dialysis patients, where 70% of the children received tube feeds, there were no significant differences in weight or height SDS up to 1 year after dialysis initiation in

patients receiving supplemental feedings compared to those not receiving supplemental feedings (38). Two smaller prospective studies also failed to detect an association between energy intake and growth (29, 97).

Commercial formulas and expressed breastmilk are preferred for tube feeding and can be supplemented, if necessary, as described above. Parents wishing to prepare their child's tube feeds by blending foods should be counseled by a qualified dietitian about safety issues with this practice, including nutritional quality, microbial contamination, and appropriate equipment and administration (98).

When oral or tube feeding is not sufficient or possible, usually as a result of intestinal failure, parenteral nutrition may be needed and the prescription must be tailored for the child with CKD. Intradialytic parenteral nutrition (IDPN) in children is rarely indicated and does not confer a benefit over enteral feeding (99). Studies are scarce (100–102) and no recommendations for its use can be given.

Ongoing oral stimulation is important in tube fed children to help in the transition to normal feeding once they have had a successful transplant (103, 104).

## Results of the Delphi survey

The Delphi survey was sent to 41 pediatric nephrologists and 28 dietitians from 26 countries, with a 68% response rate (27 pediatric nephrologists and 20 dietitians). The names of all respondents are listed under “Acknowledgments” below.

Of the 14 clinical practice recommendation statements, overall, a 94.5% consensus was achieved with a “strongly agree” or “agree” response, 4.1% had a “neutral” response, 1.2% “disagree,” and 0.4% “strongly disagree” response. On analysis of individual statements, 5 received a disagree response, the highest rate being 5.4% to statement 3.1. The respondents queried breastfeeding when there are issues with weight gain and abnormal biochemistry, and commented that supplemental feeding is necessary. These aspects are covered in the rationale supporting statements 3.3 and 3.4. One statement received a strongly disagree response, the highest rate being 5.4% to statement 1.1. The respondents queried whether stage of CKD, the presence of protein-energy wasting and hypercatabolic state should be taken into consideration. The studies supporting this statement included children with CKD2–5D, and most reported that dietary energy intakes of around 100% of that for healthy children resulted in acceptable growth.

The Taskforce team carefully reviewed all of the statements in light of these responses; none required significant change. However, there has been further clarification to the text and tables as suggested by the respondents.

## Summary of recommendations

A summary of recommendations is provided in Table 3.

## Research recommendations

We recommend the following areas of study to provide future evidence based recommendations for energy and protein requirements in children with CKD2–5D:

1. To investigate the outcomes (growth, morbidity, mortality, quality of life) associated with the provision of optimum energy and protein by tube feeding after the first 2 years of life
2. To investigate the ideal protein-energy ratio for the optimum deposition of lean mass versus fat mass and growth, assessed with multi-component body composition models
3. To investigate why some children experience growth failure while others show excessive weight gain despite receiving the SDI for energy and protein
4. To investigate oral motor development of infants and young children who are predominantly tube fed to enhance transition to oral feeding

**Acknowledgements** Vitaflo International Ltd. is a nutrition company which produces specialized clinical nutrition products for metabolic disorders, nutrition support, and specific conditions such as kidney disease. Vitaflo International Ltd. has funded the meetings held by the Pediatric Renal Nutrition Taskforce. The Pediatric Renal Nutrition Taskforce wish to confirm that Vitaflo has not influenced the development or content of these Clinical Practice Recommendations. A part of the work took place in the Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London.

**Participants in the Delphi survey** Dietitians: Aquilina A, Toronto, Canada; Aslam A, Doha, Qatar; Churchett M, Brisbane, Australia; Collins S, Sydney, Australia; Ezzat MA, Riyadh, Saudi Arabia; Fraser I, Cardiff, UK; Friedlander S, Auckland, New Zealand; Grassi MR, Milan, Italy; Gumulak A, Krakow, Poland; Horman P, Marburg, Germany; Laureti F, Rome, Italy; Mattilda A, Bangalore, India; Sarto B, Barcelona, Spain; Souter, C, Doha, Qatar; Sowula M, Krakow, Poland; Teo S, Singapore; Van den Berg A, Nijmegen, Netherlands; Van Roye L, De Haan, Belgium; Winderlich J, Melbourne, Australia; Zwolsman M, Groningen, the Netherlands.

Doctors: Agarwal I, Vellore, India; Ariceta G, Barcelona, Spain; Bakkaloglu S, Ankara, Turkey; Besoux M, Groningen, Netherlands; Cano F, Santiago, Chile; Cornelissen M, Nijmegen, Netherlands; Drozd D, Krakow, Poland; Edefonti A, Milan, Italy; Hahn D, Sydney, Australia; Hashimoto J, Tokyo, Japan; Iyengar A, Bangalore, India; Johnson L, Melbourne, Australia; Kaddourah A, Doha, Qatar; Klaus G, Marburg, Germany; Lalji R, Brisbane, Australia; Nourse P, Cape Town, South Africa; Prestidge C, Auckland, New Zealand; Prikhodina L, Moscow, Russia; Prytula A, Ghent, Belgium; Reusz G, Budapest, Hungary; Sinha A, New Delhi, India; Swaminathan, Bengaluru, India; Stabouli S, Thessaloniki, Greece; Vasudevan A, Bengaluru, India; Vondrak K, Prague, Czech Republic; Yap HK, Singapore; Zagodzón I, Gdansk, Poland.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Rees L, Jones H (2013) Nutritional management and growth in children with chronic kidney disease. *Pediatr Nephrol* 28(4):527–536
2. Schaefer F, Benner L, Borzych-Dużalka D et al (2019) Global variation of nutritional status in children undergoing chronic peritoneal dialysis: a longitudinal study of the International Pediatric Peritoneal Dialysis Network. *Sci Rep* 9:1–10
3. National Kidney Foundation Disease Outcomes Quality Initiative (2009) KDOQI clinical practice guideline for nutrition in children with CKD: 2008 update. Executive summary. *Am J Kidney Dis* 53:S11–S104
4. McAlister L, Pugh P, Greenbaum L, Haffner D, Rees L, Anderson C, Desloovere A, Nelms C, Oosterveld M, Paglialonga, F, Polderman N, Qizalbash L, Renken-Terhaerd J, Tuokkola J, Warady B, Vande Walle J, Shaw V, Shroff R. The dietary management of calcium and phosphate in children with CKD stages 2–5 and on dialysis – clinical practice recommendation from the Pediatric Renal Nutrition Taskforce. *Pediatr Nephrol* <https://doi.org/10.1007/s00467-019-04370-z>
5. American Academy of Pediatrics (2004) Classifying recommendations for clinical practice guidelines. *Pediatrics* 114:874–877
6. Food and Agriculture Organization (2001) Food and nutrition technical report series: human energy requirements. Report of a Joint FAO/WHO/UNU Expert Consultation Rome 17–24, October 2001 <http://www.fao.org/3/a-y5686pe.pdf> Accessed 17 June 2019
7. Institute of Medicine (2005) Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. Washington, DC: The National Academies Press (US) [www.nal.usda.gov/sites/default/files/fnic\\_uploads/energy\\_full\\_report.pdf](http://www.nal.usda.gov/sites/default/files/fnic_uploads/energy_full_report.pdf) Accessed 17 June 2019
8. Health Council of the Netherlands (2001) Dietary reference intakes: energy, proteins, fats and digestible carbohydrates. The Hague: Health Council of the Netherlands, 2001; publication no.2001/19R (corrected edition: June 2002). ISBN 90–5549–384-8 [www.gezondheidsraad.nl/documenten/adviezen/2001/07/18/voedingnormen-energie-eiwitten-vetten-en-verteerbare-koolhydraten](http://www.gezondheidsraad.nl/documenten/adviezen/2001/07/18/voedingnormen-energie-eiwitten-vetten-en-verteerbare-koolhydraten) with an executive summary in English. Accessed 17 June 2019
9. Scientific Advisory Committee on Nutrition (2011) Dietary Reference Values for Energy [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/)

- [file/339317/SACN\\_Dietary\\_Reference\\_Values\\_for\\_Energy.pdf](file/339317/SACN_Dietary_Reference_Values_for_Energy.pdf)  
Accessed 17 June 2019
10. Nordic Council of Ministers (2012) Nordic Nutrition Recommendations 2012 5th edition – Integrating nutrition and physical activity. <http://norden.diva-portal.org/smash/get/diva2:704251/FULLTEXT01.pdf> Accessed 17 June 2019
  11. European Food Safety Authority (2013) Panel on dietetic products, nutrition and allergies (NDA); scientific opinion on dietary reference values for energy. *EFSA Journal* 11(1):3005–112 pp doi: [10.2903/jefsa.2013.3005](https://doi.org/10.2903/jefsa.2013.3005) [www.efsa.europa.eu/efsajournal](http://www.efsa.europa.eu/efsajournal) Accessed 17 June 2019
  12. Deutschland-Austria-Confoederatio Helvetica (2015) Reference levels for nutrient intake. German Society for Nutrition, Austrian Society for Nutrition, Swiss Society for Nutrition, 2015. [www.sge-ssn.ch/grundlagen/lebensmittel-und-naehrstoffe/naehrstoffempfehlungen/dachreferenzwerte/](http://www.sge-ssn.ch/grundlagen/lebensmittel-und-naehrstoffe/naehrstoffempfehlungen/dachreferenzwerte/) Accessed 17 June 2019
  13. National Health and Medical Research Council (2006) Australian Government Department of Health and Ageing, New Zealand Ministry of Health. Nutrient Reference Values for Australia and New Zealand. Updated September 2017 <https://nhmrc.gov.au/sites/default/files/images/nutrient-reference-dietary-intakes.pdf> Accessed 17 June 2019
  14. Shapiro AC, Bandini LG, Kurtin PS (1992) Estimating energy requirements for children with renal-disease—a comparison of methods. *J Am Diet Assoc* 92:571–573
  15. Tounian P, Salaun JF, Bensman A, Melchior JC, Veinberg F, Morgant G, Fontaine JL, Girardet JP (1995) Energy-balance in children and young-adults receiving hemodialysis for chronic renal failure. *Clin Nutr* 14:341–347
  16. Marques de Aquino T, Avesani CM, Brasileiro RS, de Abreu Carvalhaes JT (2008) Resting energy expenditure of children and adolescents undergoing hemodialysis. *J Ren Nutr* 18:312–319
  17. Anderson CE, Gilbert RD, Elia M (2015) Basal metabolic rate in children with chronic kidney disease and healthy control children. *Pediatr Nephrol* 30:1995–2001
  18. Coleman JE, Watson AR, Rance CH, Moore E (1998) Gastrostomy buttons for nutritional support on chronic dialysis. *Nephrol Dial Transplant* 13:2041–2046
  19. Sahpazova E, Kuzmanovska D, Todorovska L, Bogdanovska A (2006) Nutritional status, protein intake and progression of renal failure in children. *Pediatr Nephrol* 21:1879–1883
  20. Van Dyck M, Bilem N, Proesmans W (1999) Conservative treatment for chronic renal failure from birth: a 3-year follow-up study. *Pediatr Nephrol* 13:865–869
  21. Ledermann SE, Shaw V, Trompeter RS (1999) Long-term enteral nutrition in infants and young children with chronic renal failure. *Pediatr Nephrol* 13:870–875
  22. Kari JA, Gonzalez C, Ledermann SE, Shaw V, Rees L (2000) Outcome and growth of infants with severe chronic renal failure. *Kidney Int* 57:1681–1687
  23. Ledermann SE, Scanes ME, Fernando ON, Duffy PG, Madden SJ, Trompeter RS (2000) Long-term outcome of peritoneal dialysis in infants. *J Pediatr* 136:24–29
  24. Parekh RS, Flynn JT, Smoyer WE, Milne JL, Kershaw DB, Bunchman TE, Sedman AB (2001) Improved growth in young children with severe chronic renal insufficiency who use specified nutritional therapy. *J Am Soc Nephrol* 12:2418–2426
  25. Laakkonen H, Hölttä T, Lönnqvist T, Holmberg C, Rönnholm K (2008) Peritoneal dialysis in children under two years of age. *Nephrol Dial Transplant* 23:1747–1753
  26. Warady BA, Kriley M, Lovell H, Farrell SE, Hellerstein S (1988) Growth and development of infants with end-stage renal disease receiving long-term peritoneal dialysis. *J Pediatr* 112:714–719
  27. Warady BA, Kriley M, Belden B, Hellerstein S, Alan U (1990) Nutritional and behavioural aspects of nasogastric tube feeding in infants receiving chronic peritoneal dialysis. *Adv Perit Dial* 6:265–268
  28. Brewer ED (1990) Growth of small children managed with chronic peritoneal dialysis and nasogastric tube feedings: 203-month experience in 14 patients. *Adv Perit Dial* 6:269–272
  29. Abitbol CL, Zilleruelo G, Montane B, Strauss J (1993) Growth of uremic infants on forced feeding regimens. *Pediatr Nephrol* 7:173–177
  30. Claris-Appiani A, Ardisino GL, Dacco V, Funari C, Terzi F (1995) Catch-up growth in children with chronic renal failure treated with long-term enteral nutrition. *J Parenter Enter Nutr* 19:175–178
  31. Reed EE, Roy LP, Gaskin KJ, Knight JF (1998) Nutritional intervention and growth in children with chronic renal failure. *J Ren Nutr* 8:122–126
  32. Ramage IJ, Geary DF, Harvey E, Secker DJ, Balfé JA, Balfé JW (1999) Efficacy of gastrostomy feeding in infants and older children receiving chronic peritoneal dialysis. *Perit Dial Int* 19:231–236
  33. Mencarelli F, Kiepe D, Leozappa G, Stringini G, Cappa M, Emma F (2009) Growth hormone treatment started in the first year of life in infants with chronic renal failure. *Pediatr Nephrol* 24:1039–1046
  34. Santos F, Moreno ML, Neto A, Ariceta G, Vara J, Alonso A, Bueno A, Afonso AC, Correia AJ, Muley R, Barrios V, Gómez C, Argente J (2010) Improvement in growth after 1 year of growth hormone therapy in well-nourished infants with growth retardation secondary to chronic renal failure: results of a multicenter, controlled, randomized, open clinical trial. *Clin J Am Soc Nephrol* 5:1190–1197
  35. Foreman JW, Abitbol CL, Trachtman H, Garin EH, Feld LG, Strife CF, Massie MD, Boyle RM, Chan JC (1996) Nutritional intake in children with renal insufficiency: a report of the growth failure in children with renal diseases study. *J Am Coll Nutr* 15:579–585
  36. Norman LJ, Coleman JE, Macdonald IA, Tomsett AM, Watson AR (2000) Nutrition and growth in relation to severity of renal disease in children. *Pediatr Nephrol* 15:259–265
  37. Tom A, McCauley L, Bell L, Rodd C, Espinosa P, Yu G, Yu J, Girardin C, Sharma A (1999) Growth during maintenance hemodialysis: impact of enhanced nutrition and clearance. *J Pediatr* 134:464–471
  38. Ellis EN, Yiu V, Harley F, Donaldson LA, Hand M, Warady BA, Wood EG, North American Pediatric Renal Transplant Cooperative Study (2001) The impact of supplemental feeding in young children on dialysis: a report of the North American Pediatric Renal Transplant Cooperative Study. *Pediatr Nephrol* 16:404–408
  39. Ratsch IM, Catassi C, Verrina E, Gusmano R, Appiani A, Bettinelli A, Picca S, Rizzoni G, Fabian-Bach C, Wingen AM (1992) Energy and nutrient intake of patients with mild-to-moderate chronic renal failure compared with healthy children: an Italian multicentre study. *Eur J Pediatr* 151:701–705
  40. Norman LJ, Macdonald IA, Watson AR (2004) Optimising nutrition in chronic renal insufficiency—growth. *Pediatr Nephrol* 19:1245–1252
  41. Grodstein GP, Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW (1981) Glucose absorption during continuous ambulatory peritoneal dialysis. *Kidney Int* 19:564–567
  42. Bodnar DM, Busch S, Fuchs J, Piedmonte M, Schreiber M (1993) Estimating glucose absorption in peritoneal dialysis using peritoneal equilibration tests. *Adv Perit Dial* 9:114–118
  43. Hui WF, Betoko A, Savant JD, Abraham AG, Greenbaum LA, Warady B, Moxey-Mims MM, Furth SL (2017) Assessment of dietary intake of children with chronic kidney disease. *Pediatr Nephrol* 32:485–494

44. Chen W, Ducharme-Smith K, Davis L, Hui WF, Warady BA, Furth SL, Abraham AG, Betoko A (2017) Dietary sources of energy and nutrient intake among children and adolescents with chronic kidney disease. *Pediatr Nephrol* 32:1233–1241
45. Department of Health (1991) Report on health and social subjects no 41. Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. London, The Stationery Office
46. WHO/FAO/UNU (World Health Organization/Food and Agriculture Organization of the United Nations/United Nations University) (2007) Protein and amino acid requirements in human nutrition. Report of a Joint WHO/FAO/UNU Expert Consultation. WHO Technical Report Series, No 935, 185 pp.
47. EFSA (European Food Safety Authority) (2012) Scientific Opinion on Dietary Reference Values for protein *EFSA Journal* 10(2):2557
48. AFSSA (Agence Francaise de Securite Sanitaire des Aliments) (2007) Apport en proteines: consommation, 1223 qualite, besoins et recommandations. Report of the working group. [www.anses.fr/en/system/files/NUT-Ra-Proteines.pdf](http://www.anses.fr/en/system/files/NUT-Ra-Proteines.pdf) Accessed 17 June 2019
49. Duffy T, Gunn T, Collinge J, Penchaz P (1981) The effect of varying protein quality and energy intake on the nitrogen metabolism of parenterally fed very low birthweight (<1600 g) infants. *Pediatr Res* 15:1040–1044
50. Dewey KG, Beaton G, Fjeld C, Lonnerdal B, Reeds P (1996) Protein requirements of infants and children. *Eur J Clin Nutr* 50(1):S119–S147
51. Fomom SJ, Haschke F, Ziegler EE, Nelson SE (1982) Body composition of reference children from birth to age 10 years. *Am J Clin Nutr* 35:1169–1175
52. Uauy RD, Hogg RJ, Brewer ED, Reisch JS, Cunningham C, Holliday MA (1994) Dietary protein and growth in infants with chronic renal insufficiency: a report from the Southwest Pediatric Nephrology Study Group and the University of California, San Francisco. *Pediatr Nephrol* 8:45–50
53. Wingen AM, Fabian-Bach C, Schaefer F, Mehls O (1997) Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. *Lancet* 349:1117–1123
54. Chaturvedi S, Jones C (2007) Protein restriction for children with chronic renal failure. *Cochrane Database Syst Rev* CD006863
55. Edefonti A, Picca M, Damiani B, Loi S, Ghio L, Giani M, Consalvo G, Grassi MR (1999) Dietary prescription based on estimated nitrogen balance during peritoneal dialysis. *Pediatr Nephrol* 13:253–258
56. Azocar MA, Cano FJ, Marin V, Delucchi MA, Rodriguez EE (2004) Body composition in children on peritoneal dialysis. *Adv Perit Dial* 20:231–236
57. Boaz M, Smetana S (1996) Regression equation predicts dietary phosphorus intake from estimate of dietary protein intake. *J Am Diet Assoc* 96:1268–1270
58. Sedlacek M, Dimaano F, Uribarri J (2000) Relationship between phosphorus and creatinine clearance in peritoneal dialysis: clinical implications. *Am J Kidney Dis* 36:1020–1024
59. Zadik Z, Frishberg Y, Drukker A, Blachar Y, Lotan D, Levi S, Reifen R (1998) Excessive dietary protein and suboptimal caloric intake have a negative effect on the growth of children with chronic renal disease before and during growth hormone therapy. *Metabolism* 47:264–268
60. Quan A, Baum M (1996) Protein losses in children on continuous cycler peritoneal dialysis. *Pediatr Nephrol* 10:728–731
61. Wolfson M, Jones MR, Kopple JD (1982) Amino acid losses during hemodialysis with infusion of amino acids and glucose. *Kidney Int* 21(3):500–506
62. Ikizler TA, Flakoll PJ, Parker RA, Hakim RM (1994) Amino acid and albumin losses during hemodialysis. *Kidney Int* 46(3):830–837
63. Chazot C, Shahmir E, Matias B, Laidlaw S (1997) Dialytic nutrition: provision of amino acids in dialysate during hemodialysis. *Kidney Int* 52(6):1663–1670
64. Fischbach M, Terzic J, Menouer S, Dheu C, Soskin S, Helmstetter A, Burger MC (2006) Intensified and daily hemodialysis in children might improve statural growth. *Pediatr Nephrol* 21:1746–1752
65. Kramer MS, Kakuma R (2012) Optimal duration of exclusive breastfeeding. *Cochrane Database Syst Rev*:CD003517
66. Steele JR, Meskell RJ, Foy J (2013) Determining the osmolality of over-concentrated and supplemented infant formulas. *J Hum Nutr Diet* 26:32–37
67. Manickavasagar B, McArdle AJ, Yadav P, Shaw V, Dixon M, Blomhoff R, Connor GO, Rees L, Ledermann S, Van't Hoff W, Shroff R (2015) Hypervitaminosis a is prevalent in children with CKD and contributes to hypercalcemia. *Pediatr Nephrol* 30:317–325
68. Pereira AM, Hamani N, Nogueira PC, Carvalhaes JT (2000) Oral vitamin intake in children receiving long-term dialysis. *J Ren Nutr* 10:24–29
69. Joyce T, Court Brown F, Wallace D, Reid CJD, Sinha MD (2018) Trace element and vitamin concentrations in paediatric dialysis patients. *Pediatr Nephrol* 33:159–165
70. Ellis EN, Pearson D, Champion B, Wood EG (1995) Outcome of infants on chronic peritoneal dialysis. *Adv Perit Dial* 11:266–269
71. Quinlan C, Bates M, Sheils A, Dolan N, Riordan M, Awan A (2013) Chronic hemodialysis in children weighing less than 10 kg. *Pediatr Nephrol* 28:803–809
72. Evans S, Daly A, Ashmore C, Gokmen-Ozel H, Dileva R, Dumbleton B, Chahal S, Macdonald A (2013) Nutritional content of modular feeds: how accurate is feed production? *Arch Dis Child* 98:184–188
73. Samaan S, Secker D (2014) Oral feeding challenges in infants with chronic kidney disease. *Infant Child Adolesc Nutr* 6(3):164–171
74. Hojsak I, Bronsky J, Campoy C, Domellöf M, Embleton N, Fidler Mis N, Hulst J, Indrio F, Lapillonne A, Mølgaard C, Vora R, Fewtrell M, ESPGHAN Committee on Nutrition (2018) Young child formula: a position paper by the ESPGHAN committee on nutrition. *J Pediatr Gastroenterol Nutr* 66(1):177–185
75. Dello Strologo L, Principato F, Sinibaldi D, Claris Appiani A, Terzi F, Dartois AM, Rizzoni G (1997) Feeding dysfunction in infants with severe chronic renal failure after long-term nasogastric tube-feeding. *Pediatr Nephrol* 11:84–86
76. Ruley EJ, Bock GH, Kerzner B, Abbott AW, Majd M, Chatoor I (1989) Feeding disorders and gastroesophageal reflux in infants with chronic renal failure. *Pediatr Nephrol* 3:424–429
77. Armstrong JE, Laing DG, Wilkes FJ, Kainer G (2010) Smell and taste function in children with chronic kidney disease. *Pediatr Nephrol* 25:1497–1504
78. Buyan N, Bideci A, Ozkaya O, Ortac E, Bakkaloglu S, Gonen S, Peru H, Soylemezoglu O, Cinaz P (2006) Leptin and resistin levels and their relationships with glucose metabolism in children with chronic renal insufficiency and undergoing dialysis. *Nephrology* 11:192–196
79. Maggio MC, Montaperto D, Maringhini S, Corrado C, Gucciardino E, Corsello G (2014) Adiponectin, resistin and leptin in paediatric chronic renal failure: correlation with auxological and endocrine profiles. *J Nephrol* 27:275–279
80. Agras PI, Baskin E, Cengiz N, Haberal A, Ozbek N (2013) Leptin and plasminogen activator inhibitor-1 levels in children on chronic dialysis. *Ren Fail* 35:1079–1084

81. Besbas N, Ozaltin F, Coşkun T, Ozalp S, Saatçi U, Bakkaloğlu A, El Nahas AM (2003) Relationship of leptin and insulin-like growth factor I to nutritional status in hemodialyzed children. *Nephrol Dial Transplant* 18:1255–1259
82. Nüsken KD, Gröschl M, Rauh M, Stöhr W, Rascher W, Dötsch J (2004) Effect of renal failure and dialysis on circulating ghrelin concentration in children. *Nephrol Dial Transplant* 19(8):2156–2157
83. Büscher AK, Büscher R, Hauffa BP, Hoyer PF (2010) Alterations in appetite-regulating hormones influence protein-energy wasting in pediatric patients with chronic kidney disease. *Pediatr Nephrol* 25:2295–2301
84. Daschner M, Tönshoff B, Blum WF, Englaro P, Wingen AM, Schaefer F, Wühl E, Rascher W, Mehls O (1998) Inappropriate elevation of serum leptin levels in children with chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. *J Am Soc Nephrol* 9:1074–1079
85. Nehus E, Furth S, Warady B, Mitsnefes M (2014) Correlates of leptin in children with chronic kidney disease. *J Pediatr* 165:825–829
86. Arbeiter AK, Büscher R, Petersenn S, Hauffa BP, Mann K, Hoyer PF (2009) Ghrelin and other appetite-regulating hormones in paediatric patients with chronic renal failure during dialysis and following kidney transplantation. *Nephrol Dial Transplant* 24:643–646
87. Naufel MF, Bordon M, de Aquino TM, Ribeiro EB, de Abreu Carvalhaes JT (2010) Plasma levels of acylated and total ghrelin in pediatric patients with chronic kidney disease. *Pediatr Nephrol* 25:2477–2482
88. Monzani A, Perrone M, Prodam F, Moia S, Genoni G, Testa S, Paglialonga F, Rapa A, Bona G, Montini G, Edefonti A (2018) Unacylated ghrelin and obestatin: promising biomarkers of protein energy wasting in children with chronic kidney disease. *Pediatr Nephrol* 33:661–672
89. Arnold WC, Danford D, Holliday MA (1983) Effects of caloric supplementation on growth in children with uremia. *Kidney Int* 24:205–209
90. Coleman JE, Norman LJ, Watson AR (1999) Provision of dietetic care in children on chronic peritoneal dialysis. *J Ren Nutr* 9(3): 145–148
91. Balfe JW, Secker DJ, Coulter PE, Balfe JA, Geary DF (1990) Tube feeding in children on chronic peritoneal dialysis. *Adv Perit Dial* 6:257–261
92. Mekahli D, Shaw V, Ledermann SE, Rees L (2010) Long-term outcome of infants with severe chronic kidney disease. *Clin J Am Soc Nephrol* 5:10–17
93. Rees L, Rigden SP, Ward GM (1989) Chronic renal failure and growth. *Arch Dis Child* 64:573–577
94. Rees L, Azocar M, Borzych D, Watson AR, Büscher A, Edefonti A, Bilge I, Askenazi D, Leozappa G, Gonzales C, van Hoeck K, Secker D, Zurowska A, Rönnholm K, Bouts AH, Stewart H, Ariceta G, Ranchin B, Warady BA, Schaefer F, International Pediatric Peritoneal Dialysis Network (IPPN) registry (2011) Growth in very young children undergoing chronic peritoneal dialysis. *J Am Soc Nephrol* 22:2303–2312
95. Sienna JL, Saqan R, Teh JC, Frieling ML, Secker D, Cornelius V, Geary DF (2010) Body size in children with chronic kidney disease after gastrostomy tube feeding. *Pediatr Nephrol* 25:2115–2121
96. Mir S, Ozkayin N, Akgun A (2005) The role of keto acids in the supportive treatment of children with chronic renal failure. *Pediatr Nephrol* 20:950–955
97. Van Dyck M, Sidler S, Proesmans W (1998) Chronic renal failure in infants: effect of strict conservative treatment on growth. *Eur J Pediatr* 157:759–762
98. Breaks A, Smith C, Bloch S, Morgan S (2018) Blended diets for gastrostomy fed children and young people: a scoping review. *J Hum Nutr Diet* 31(5):634–646
99. Dudley J, Rogers R, Sealy L (2014) Renal consequences of parenteral nutrition. *Pediatr Nephrol* 29(3):375–385
100. Goldstein SL, Baronette S, Gambrell TV, Currier H, Brewer ED (2002) nPCR assessment and IDPN treatment of malnutrition in pediatric hemodialysis patients. *Pediatr Nephrol* 17:531–534
101. Krause I, Shamir R, Davidovits M, Frishman S, Cleper R, Gamzo Z, Poraz I, Eisenstein B (2002) Intradialytic parenteral nutrition in malnourished children treated with hemodialysis. *J Renal Nutr* 12: 55–59
102. Haskin O, Sutherland SM, Wong CJ (2017) The effect of intradialytic intralipid therapy in pediatric hemodialysis patients. *J Renal Nutr* 27:132–137
103. Pugh P, Watson AR (2006) Transition from gastrostomy to oral feeding following renal transplantation. *Adv Perit Dial* 22:153–157
104. Ledermann S (2005) When should gastrostomy tubes be removed following successful renal transplantation? *Pediatr Transplant* 9(5):553–554

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.